Education
About Us
Working with TipRanks
Follow Us
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
BBOT Stock Chart & Stats
$12.21
--
Market closed
$12.21
--
Day’s Range― - ―
52-Week Range$8.50 - $14.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$1.01B
Enterprise ValueN/A
Total Cash (Recent Filing)$468.29M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)60.3
Beta0.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,196,710
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.00
P/FCF Ratio-228.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$23.75Price Target Upside94.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNumerous near-term value inflection points ahead, with upcoming catalysts for investors including updated data from the ONKORAS-101 trial for BBO-8520.
Drug DevelopmentBBO-11818 has both monotherapy and combinatorial potential, demonstrating strong anti-tumor responses in vivo.
Financial StabilityBridgeBio Oncology ended with $468.3M in cash and cash equivalents, providing an operational runway into 2028.
Bears Say
Conflicts Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Financial PerformanceBridgeBio Oncology recorded a net loss of $1.03 per share compared to the previously estimated net loss of $0.35 per share.
Regulatory And Commercial RisksRisks include clinical setbacks, inability to advance assets into pivotal trials, and failure to secure regulatory approvals.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $8.50 and its highest was $14.04 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $1.01B.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Currently, no data Available
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 79,196,710 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
BridgeBio Oncology Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.75 (94.51% Upside)
$23.75 (94.51% Upside)
Hedge Fund Trend
Increased
By 7.7M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
2.53%
Trailing 12-Months
Asset Growth
3.96%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BBOT Stock 12 Month Forecast
Average Price Target
$23.75
▲(94.51% Upside)
Technical Analysis
dMY Squared Technology Group, Inc. Class A
―
AlphaVest Acquisition Corporation
―
Horizon Space Acquisition I Corporation
―
Four Leaf Acquisition Corporation Class A
―
Quetta Acquisition Corp.
―